 |
BioWorld-International-2011-02-09
Fund Pressures Actelionto Put Up a For-Sale Sign
Zealand/Sanofi's Lixisenatide as Effective as Lilly's Byetta
LONDON – Zealand Pharma A/S advanced its hopes of delivering the second once-daily glucagon-like peptide-1 agonist (GLP-1) to the market, announcing the results from a Phase III trial comparing its product lixisenatide to exenatide (Byetta), which is administered twice daily. (BioWorld International)